Phase 3 REVEAL trial details 124I-evuzamitide PET/CT design for cardiac amyloidosis diagnosis.
Design and Rationale of the REVEAL PET Study: A Study of 124I-evuzamitide to Diagnose Cardiac Amyloidosis.
Abstract
Phase 3 REVEAL trial design evaluates 124I-evuzamitide PET/CT for diagnosing cardiac amyloidosis, targeting sensitivity and specificity against standard-of-care.